IBI3003 not checked

Innovent

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
4 active
4 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Recombinant humanized anti-GPRC5D/BCMA/CD3 trispecific antibody injection”In the company’s words, NCT07764861 on ClinicalTrials.gov
Tested for
Multiple Myeloma (3 trials), Relapsed or Refractory Multiple Myeloma
Main trialPhase 3
“The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd or SVd)”In the company’s words, NCT07623798 on ClinicalTrials.gov
Other names
trispecific antibody

Other drugs for Multiple Myeloma

All 133 drugs for Multiple Myeloma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 May 2029 A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Phase 2Not yet recruiting 31 Dec 2026 A Open-Label Phase in Participants With Multiple Myeloma
Phase 1/2Recruiting 31 Oct 2026 A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1/2Recruiting 30 Jun 2027 A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow IBI3003

Following is part of Solo: you see every change to IBI3003 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in